False negative and false positive results of tumoral markers: Their limitation in the clinical practice. Clinical applications to CA-125

Revista Clinica Espanola

Volumn 201, Issue 12, 2001, Pages 715-717

  Jimenez Lacave A ^a   Allende Monclus M ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 1; MONOCLONAL ANTIBODY; PACLITAXEL; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN DETECTION; ARTICLE; CANCER CELL; CANCER RECURRENCE; CANCER SCREENING; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DRUG MONITORING; FEMALE; HUMAN; LAPAROTOMY; MICROSCOPY; OVARY CANCER; PROGNOSIS; SECOND LOOK SURGERY; LABORATORY DIAGNOSIS; NEOPLASM;

CA-125 ANTIGEN; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035544295     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2565(01)70959-9     Document Type: Article

References (9)

1. What defines a useful marker of metastasis in human
2. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor
3. Statistical considerations and modeling of clinical utility of tumor markers
4. CA-125: Fundamental and clinical aspects
5. Markedly elevated CA-125 in hepatic cirrhosis
6. Tumor markers in gynaecological cancers-EGTM recommendations (editorial)
7. OVX1 radioimmunoassay complements CA 125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures
8. Daxenbichler. Regulation of CA-125 expression in cultured human carcinoma cells
9. More than 15 years of CA-125: What is know about the antigen, its structures and its function